Cellectis Achieves Partial Termination of Its Contract with Servier
Biotechnology company Cellectis announces that the arbitration tribunal has issued its decision in the dispute with Servier. The tribunal has ruled for a partial termination of the licensing agreement for the UCART19 V1 product and dismissed all other claims from the parties.
Arbitration Decision Announced
According to the press release dated December 15, 2025, the arbitration tribunal resolved the dispute between Cellectis and Servier Laboratories, along with the Servier International Research Institute IRIS SARL. The dispute centered on the licensing agreement signed between the two parties on March 6, 2019, and its subsequent amendments. The tribunal's decision resulted in a partial termination of the contract for the UCART19 V1 product, also known as ALLO-501 by Allogene company. Additionally, the tribunal dismissed all other claims from the parties.
Mandatory Negotiations with Allogene
According to the company, the arbitration tribunal has stipulated that Cellectis must initiate good faith negotiations with Allogene, should they request it. These discussions would focus on granting a direct license to Allogene for the UCART19 V1 product. This requirement is one of the main practical consequences of the arbitration decision for Cellectis. The press release does not specify the timelines or concrete terms of these potential negotiations.
About Cellectis
Cellectis is a clinical-stage biotechnology company that develops cellular and gene therapies using its genome editing platform. The company, headquartered in Paris, also has facilities in New York and Raleigh in the United States. It specializes in the development of allogeneic immunotherapies based on CAR-T cells for the treatment of cancer patients. Cellectis controls the entire production chain of cellular and gene therapies through its internal manufacturing capabilities.
